Veradermics MANE
Veradermics reported a $21 million net loss for Q3 2026.
Veradermics (MANE) filed a 10-Q with the SEC on Nov 10, 2026, 4:58 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001827635-26-000043
- Net loss of $21 million for the three months ended Sep 30, 2026
- Diluted EPS of -$2.12 for the three months ended Sep 30, 2026
- Cash and equivalents of $132.16 million as of Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
1 new risk factor · 2 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Operating income and margin | −$28.78M | −$29.55M | +2.6% |
| Net income | −$21M | −$23.5M | +11% |
| Operating cash flow | −$22.95M | −$14.49M | −58% |
| Cash | $132.16M | $319.33M | −59% |
New risk factors (1)
- We may be unable to complete our registration-directed trials for any product candidates we may develop, including VDPHL01.
Removed risk factors (2)
- As an organization, we have only recently initiated registration-directed clinical trials, and may be unable to complete such trials for any product candidates we may develop, including VDPHL01.
- We will not receive significant additional funds upon the exercise of the Pre-Funded Warrants sold in the Private Placement. +1 more paragraph